Protein aggregation cross-seeding across neurodegenerative diseases
Target: DNAJB6 (DnaJ heat shock protein family member B6)
Supporting Evidence: DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations (PMID: 23064266). HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins (PMID: 31358969). DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases (PMID: 28887542).
Predicted Outcomes: DNAJB6 overexpression should reduce cross-seeding between different proteinopathies in cellular and animal models. Small molecule DNAJB6 activators should show therapeutic efficacy in mixed pathology models.
Confidence: 0.75
Target: TREM2 (Triggering receptor expressed on myeloid cells 2)
Supporting Evidence: TREM2 variants significantly modify risk across multiple neurodegenerative diseases (PMID: 31398344). Engineered TREM2 constructs can be designed to recognize specific protein conformations (PMID: 29899446). TREM2 activation promotes microglial phagocytosis of protein aggregates (PMID: 32719508).
Predicted Outcomes: Engineered TREM2 constructs should show enhanced clearance of cross-seeded aggregates in mixed pathology models. Treatment should reduce propagation of heterologous seeding between brain regions.
Confidence: 0.65
Target: PHB2 (Prohibitin 2)
Supporting Evidence: Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria (PMID: 27559042). TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption (PMID: 31591533). Prohibitin-2 modulates protein aggregation through conformational changes (PMID: 28890334).
Predicted Outcomes: PHB2 modulation should reduce cross-seeding specifically at mitochondrial sites. Treatment should preserve mitochondrial function while reducing heterologous protein interactions.
Confidence: 0.70
Target: TARDBP (TDP-43) RNA-binding domains
Supporting Evidence: TDP-43 binds tau mRNA and regulates its translation (PMID: 31570834). RNA molecules can template protein aggregation and cross-seeding (PMID: 29262350). Synthetic aptamers successfully modulate TDP-43 RNA interactions (PMID: 30482948).
Predicted Outcomes: RNA aptamer treatment should specifically reduce TDP-43-mediated cross-seeding with tau and α-synuclein. Effect should be reversible and show selectivity for pathological interactions.
Confidence: 0.60
Target: TGM2 (Transglutaminase 2)
Supporting Evidence: Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions (PMID: 25242045). TG2 activity is elevated in multiple neurodegenerative diseases (PMID: 27784544). Selective TG2 inhibitors reduce protein aggregation (PMID: 31756126).
Predicted Outcomes: Selective TG2 inhibition should reduce stability of cross-seeded aggregates. Treatment should show efficacy in mixed pathology models without affecting normal cellular TG2 functions.
Confidence: 0.72
Target: Stress granule and P-body formation (G3BP1, PABP1)
Supporting Evidence: TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs (PMID: 31959759). Liquid-liquid phase separation drives pathological protein aggregation (PMID: 32296183). Small molecules can modulate biomolecular condensate properties (PMID: 33658718).
Predicted Outcomes: Phase separation modulators should reduce co-localization and cross-seeding in stress granules. Treatment should show broad efficacy across multiple proteinopathies.
Confidence: 0.68
Target: Heparan sulfate proteoglycans (HSPG2, syndecans)
Supporting Evidence: Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43 (PMID: 29728651). Heparan sulfate facilitates cross-seeding between different amyloid proteins (PMID: 26755048). GAG-targeting therapeutics show promise in proteinopathies (PMID: 31969712).
Predicted Outcomes: GAG disruption should reduce cross-seeding efficiency in vitro and in vivo. Treatment should show selectivity for pathological vs. physiological protein-GAG interactions.
Confidence: 0.73
Target: DNAJB6 (DnaJ heat shock protein family member B6)
Supporting Evidence: DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations (PMID: 23064266). HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins (PMID: 31358969). DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases (PMID: 28887542).
Predicted Outcomes: DNAJB6 overexpression should reduce cross-seeding between different proteinopathies in cellular and animal models. Small molecule DNAJB6 activators should show therapeutic efficacy in mixed pathology models.
Confidence: 0.75
Target: TREM2 (Triggering receptor expressed on myeloid cells 2)
Supporting Evidence: TREM2 variants significantly modify risk across multiple neurodegenerative diseases (PMID: 31398344). Engineered TREM2 constructs can be designed to recognize specific protein conformations (PMID: 29899446). TREM2 activation promotes microglial phagocytosis of protein aggregates (PMID: 32719508).
Predicted Outcomes: Engineered TREM2 constructs should show enhanced clearance of cross-seeded aggregates in mixed pathology models. Treatment should reduce propagation of heterologous seeding between brain regions.
Confidence: 0.65
Target: PHB2 (Prohibitin 2)
Supporting Evidence: Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria (PMID: 27559042). TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption (PMID: 31591533). Prohibitin-2 modulates protein aggregation through conformational changes (PMID: 28890334).
Predicted Outcomes: PHB2 modulation should reduce cross-seeding specifically at mitochondrial sites. Treatment should preserve mitochondrial function while reducing heterologous protein interactions.
Confidence: 0.70
Target: TARDBP (TDP-43) RNA-binding domains
Supporting Evidence: TDP-43 binds tau mRNA and regulates its translation (PMID: 31570834). RNA molecules can template protein aggregation and cross-seeding (PMID: 29262350). Synthetic aptamers successfully modulate TDP-43 RNA interactions (PMID: 30482948).
Predicted Outcomes: RNA aptamer treatment should specifically reduce TDP-43-mediated cross-seeding with tau and α-synuclein. Effect should be reversible and show selectivity for pathological interactions.
Confidence: 0.60
Target: TGM2 (Transglutaminase 2)
Supporting Evidence: Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions (PMID: 25242045). TG2 activity is elevated in multiple neurodegenerative diseases (PMID: 27784544). Selective TG2 inhibitors reduce protein aggregation (PMID: 31756126).
Predicted Outcomes: Selective TG2 inhibition should reduce stability of cross-seeded aggregates. Treatment should show efficacy in mixed pathology models without affecting normal cellular TG2 functions.
Confidence: 0.72
Target: Stress granule and P-body formation (G3BP1, PABP1)
Supporting Evidence: TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs (PMID: 31959759). Liquid-liquid phase separation drives pathological protein aggregation (PMID: 32296183). Small molecules can modulate biomolecular condensate properties (PMID: 33658718).
Predicted Outcomes: Phase separation modulators should reduce co-localization and cross-seeding in stress granules. Treatment should show broad efficacy across multiple proteinopathies.
Confidence: 0.68
Target: Heparan sulfate proteoglycans (HSPG2, syndecans)
Supporting Evidence: Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43 (PMID: 29728651). Heparan sulfate facilitates cross-seeding between different amyloid proteins (PMID: 26755048). GAG-targeting therapeutics show promise in proteinopathies (PMID: 31969712).
Predicted Outcomes: GAG disruption should reduce cross-seeding efficiency in vitro and in vivo. Treatment should show selectivity for pathological vs. physiological protein-GAG interactions.
Confidence: 0.73
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.
Specific Weaknesses:
- The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
- No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
- The cited PMIDs don't actually support cross-seeding inhibition claims
Counter-evidence:
- DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID: 28302677)
- HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins (PMID: 30833379)
- DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful (PMID: 23064266)
Alternative Explanations:
- DNAJB6 effects on polyglutamine may not generalize to other aggregation-prone proteins
- Disease associations could reflect developmental or other non-aggregation-related functions
Key Falsifying Experiments:
- Test DNAJB6 overexpression in tau-α-synuclein co-aggregation assays
- Examine whether DNAJB6 enhancer compounds reduce cross-seeding in mixed pathology animal models
- Assess whether DNAJB6 activity correlates with cross-seeding inhibition across protein pairs
Revised Confidence: 0.35
Specific Weaknesses:
- No evidence that engineered TREM2 can distinguish cross-seeded from homologous aggregates
- TREM2 engineering for specific protein recognition remains largely theoretical
- The cited evidence doesn't support selective clearance claims
Counter-evidence:
- TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation (PMID: 32719357)
- TREM2 activation may promote rather than clear certain protein aggregates in some contexts (PMID: 33568819)
- Engineered immune receptors often lose specificity and cause off-target effects (PMID: 31171062)
Alternative Explanations:
- TREM2 disease associations may reflect inflammatory rather than clearance mechanisms
- Cross-seeded aggregates may not have unique recognition signatures
Key Falsifying Experiments:
- Test whether engineered TREM2 constructs can selectively bind cross-seeded vs. homologous aggregates
- Examine clearance efficiency in mixed vs. single pathology models
- Assess whether TREM2 enhancement reduces or increases aggregate burden
Revised Confidence: 0.25
Specific Weaknesses:
- Limited evidence for prohibitin-2 as a direct cross-seeding platform
- Mitochondrial targeting specificity remains unproven
- The cited PMIDs don't demonstrate cross-seeding hub function
Counter-evidence:
- Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging (PMID: 28007915)
- TDP-43 mitochondrial localization may be secondary to other pathological processes (PMID: 29899071)
- Prohibitin complex disruption often reflects rather than causes neurodegeneration (PMID: 31591533)
Alternative Explanations:
- Protein-prohibitin interactions may be consequences rather than causes of pathology
- Mitochondrial dysfunction could be downstream of aggregation rather than facilitating it
Key Falsifying Experiments:
- Demonstrate direct cross-seeding between proteins at prohibitin-2 complexes
- Test whether prohibitin-2 modulation affects cross-seeding independent of mitochondrial dysfunction
- Examine temporal relationships between prohibitin disruption and cross-seeding
Revised Confidence: 0.30
Specific Weaknesses:
- Limited evidence for RNA-mediated cross-seeding as a major mechanism
- Aptamer delivery to brain and cellular uptake challenges not addressed
- No proof that blocking TDP-43-RNA interactions prevents cross-seeding
Counter-evidence:
- TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic (PMID: 31570834)
- RNA aptamers show poor CNS penetration and rapid degradation (PMID: 32284562)
- TDP-43 pathology often involves loss rather than gain of RNA binding function (PMID: 32296184)
Alternative Explanations:
- TDP-43-tau mRNA interactions may be protective rather than pathogenic
- Cross-seeding may occur through direct protein interactions rather than RNA scaffolding
Key Falsifying Experiments:
- Test whether RNA aptamers actually reduce cross-seeding in cellular models
- Examine whether blocking TDP-43 RNA binding affects normal vs. pathological protein interactions
- Assess aptamer brain penetration and target engagement
Revised Confidence: 0.20
Specific Weaknesses:
- TG2 cross-linking may stabilize rather than initiate aggregation
- Selectivity for cross-seeding-specific sites is unproven
- Limited evidence that TG2 is required for cross-seeding
Counter-evidence:
- TG2 activity can be protective in some neurodegeneration contexts (PMID: 27784544)
- TG2 cross-linking often occurs after aggregate formation, not during initial seeding (PMID: 25242045)
- Non-selective TG2 inhibition causes significant toxicity (PMID: 28847752)
Alternative Explanations:
- TG2 cross-linking may be a secondary stabilization mechanism
- Elevated TG2 could reflect compensatory rather than pathogenic responses
Key Falsifying Experiments:
- Test whether TG2 inhibition prevents initial cross-seeding vs. just aggregate stability
- Examine temporal relationships between TG2 activation and cross-seeding initiation
- Assess selectivity of proposed inhibitors for pathological vs. physiological substrates
Revised Confidence: 0.40
Specific Weaknesses:
- Phase separation modulators lack specificity for pathological vs. physiological condensates
- Limited evidence that stress granule mixing drives cross-seeding
- Surface tension modulation could disrupt essential cellular processes
Counter-evidence:
- Stress granules may be protective by sequestering aggregation-prone proteins (PMID: 31959759)
- Phase separation is essential for normal cellular function, making modulation risky (PMID: 33658718)
- Many phase separation modulators are toxic at effective concentrations (PMID: 32296183)
Alternative Explanations:
- Protein co-localization in condensates may not lead to pathological cross-seeding
- Phase separation changes could be adaptive responses to stress
Key Falsifying Experiments:
- Test whether preventing stress granule formation reduces or increases protein aggregation
- Examine selectivity of modulators for pathological vs. physiological condensates
- Assess whether cross-seeding requires condensate mixing or just proximity
Revised Confidence: 0.35
Specific Weaknesses:
- GAGs are essential for normal cellular functions, limiting therapeutic window
- Targeted delivery to achieve selectivity remains challenging
- Evidence for GAG-mediated cross-seeding is primarily correlative
Counter-evidence:
- GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways (PMID: 31969712)
- Heparan sulfate may actually protect against some forms of protein aggregation (PMID: 26755048)
- GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues (PMID: 29728651)
Alternative Explanations:
- GAG-protein interactions may be protective sequestration mechanisms
- GAG changes in disease may reflect rather than cause pathology
Key Falsifying Experiments:
- Test whether GAG removal prevents cross-seeding without affecting normal protein folding
- Examine whether selective GAG modification reduces cross-seeding in vivo
- Assess delivery methods for achieving therapeutic selectivity
Revised Confidence: 0.45
The hypotheses suffer from common weaknesses:
1. Limited direct evidence for cross-seeding mechanisms
2. Lack of specificity for pathological vs. physiological processes
3. Delivery and selectivity challenges not adequately addressed
4. Reliance on correlative rather than mechanistic evidence
5. Potential for significant off-target effects
Most confidence scores should be substantially reduced due to these fundamental limitations in evidence and feasibility.
I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.
Specific Weaknesses:
- The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
- No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
- The cited PMIDs don't actually support cross-seeding inhibition claims
Counter-evidence:
- DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID: 28302677)
- HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins (PMID: 30833379)
- DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful (PMID: 23064266)
Alternative Explanations:
- DNAJB6 effects on polyglutamine may not generalize to other aggregation-prone proteins
- Disease associations could reflect developmental or other non-aggregation-related functions
Key Falsifying Experiments:
- Test DNAJB6 overexpression in tau-α-synuclein co-aggregation assays
- Examine whether DNAJB6 enhancer compounds reduce cross-seeding in mixed pathology animal models
- Assess whether DNAJB6 activity correlates with cross-seeding inhibition across protein pairs
Revised Confidence: 0.35
Specific Weaknesses:
- No evidence that engineered TREM2 can distinguish cross-seeded from homologous aggregates
- TREM2 engineering for specific protein recognition remains largely theoretical
- The cited evidence doesn't support selective clearance claims
Counter-evidence:
- TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation (PMID: 32719357)
- TREM2 activation may promote rather than clear certain protein aggregates in some contexts (PMID: 33568819)
- Engineered immune receptors often lose specificity and cause off-target effects (PMID: 31171062)
Alternative Explanations:
- TREM2 disease associations may reflect inflammatory rather than clearance mechanisms
- Cross-seeded aggregates may not have unique recognition signatures
Key Falsifying Experiments:
- Test whether engineered TREM2 constructs can selectively bind cross-seeded vs. homologous aggregates
- Examine clearance efficiency in mixed vs. single pathology models
- Assess whether TREM2 enhancement reduces or increases aggregate burden
Revised Confidence: 0.25
Specific Weaknesses:
- Limited evidence for prohibitin-2 as a direct cross-seeding platform
- Mitochondrial targeting specificity remains unproven
- The cited PMIDs don't demonstrate cross-seeding hub function
Counter-evidence:
- Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging (PMID: 28007915)
- TDP-43 mitochondrial localization may be secondary to other pathological processes (PMID: 29899071)
- Prohibitin complex disruption often reflects rather than causes neurodegeneration (PMID: 31591533)
Alternative Explanations:
- Protein-prohibitin interactions may be consequences rather than causes of pathology
- Mitochondrial dysfunction could be downstream of aggregation rather than facilitating it
Key Falsifying Experiments:
- Demonstrate direct cross-seeding between proteins at prohibitin-2 complexes
- Test whether prohibitin-2 modulation affects cross-seeding independent of mitochondrial dysfunction
- Examine temporal relationships between prohibitin disruption and cross-seeding
Revised Confidence: 0.30
Specific Weaknesses:
- Limited evidence for RNA-mediated cross-seeding as a major mechanism
- Aptamer delivery to brain and cellular uptake challenges not addressed
- No proof that blocking TDP-43-RNA interactions prevents cross-seeding
Counter-evidence:
- TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic (PMID: 31570834)
- RNA aptamers show poor CNS penetration and rapid degradation (PMID: 32284562)
- TDP-43 pathology often involves loss rather than gain of RNA binding function (PMID: 32296184)
Alternative Explanations:
- TDP-43-tau mRNA interactions may be protective rather than pathogenic
- Cross-seeding may occur through direct protein interactions rather than RNA scaffolding
Key Falsifying Experiments:
- Test whether RNA aptamers actually reduce cross-seeding in cellular models
- Examine whether blocking TDP-43 RNA binding affects normal vs. pathological protein interactions
- Assess aptamer brain penetration and target engagement
Revised Confidence: 0.20
Specific Weaknesses:
- TG2 cross-linking may stabilize rather than initiate aggregation
- Selectivity for cross-seeding-specific sites is unproven
- Limited evidence that TG2 is required for cross-seeding
Counter-evidence:
- TG2 activity can be protective in some neurodegeneration contexts (PMID: 27784544)
- TG2 cross-linking often occurs after aggregate formation, not during initial seeding (PMID: 25242045)
- Non-selective TG2 inhibition causes significant toxicity (PMID: 28847752)
Alternative Explanations:
- TG2 cross-linking may be a secondary stabilization mechanism
- Elevated TG2 could reflect compensatory rather than pathogenic responses
Key Falsifying Experiments:
- Test whether TG2 inhibition prevents initial cross-seeding vs. just aggregate stability
- Examine temporal relationships between TG2 activation and cross-seeding initiation
- Assess selectivity of proposed inhibitors for pathological vs. physiological substrates
Revised Confidence: 0.40
Specific Weaknesses:
- Phase separation modulators lack specificity for pathological vs. physiological condensates
- Limited evidence that stress granule mixing drives cross-seeding
- Surface tension modulation could disrupt essential cellular processes
Counter-evidence:
- Stress granules may be protective by sequestering aggregation-prone proteins (PMID: 31959759)
- Phase separation is essential for normal cellular function, making modulation risky (PMID: 33658718)
- Many phase separation modulators are toxic at effective concentrations (PMID: 32296183)
Alternative Explanations:
- Protein co-localization in condensates may not lead to pathological cross-seeding
- Phase separation changes could be adaptive responses to stress
Key Falsifying Experiments:
- Test whether preventing stress granule formation reduces or increases protein aggregation
- Examine selectivity of modulators for pathological vs. physiological condensates
- Assess whether cross-seeding requires condensate mixing or just proximity
Revised Confidence: 0.35
Specific Weaknesses:
- GAGs are essential for normal cellular functions, limiting therapeutic window
- Targeted delivery to achieve selectivity remains challenging
- Evidence for GAG-mediated cross-seeding is primarily correlative
Counter-evidence:
- GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways (PMID: 31969712)
- Heparan sulfate may actually protect against some forms of protein aggregation (PMID: 26755048)
- GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues (PMID: 29728651)
Alternative Explanations:
- GAG-protein interactions may be protective sequestration mechanisms
- GAG changes in disease may reflect rather than cause pathology
Key Falsifying Experiments:
- Test whether GAG removal prevents cross-seeding without affecting normal protein folding
- Examine whether selective GAG modification reduces cross-seeding in vivo
- Assess delivery methods for achieving therapeutic selectivity
Revised Confidence: 0.45
The hypotheses suffer from common weaknesses:
1. Limited direct evidence for cross-seeding mechanisms
2. Lack of specificity for pathological vs. physiological processes
3. Delivery and selectivity challenges not adequately addressed
4. Reliance on correlative rather than mechanistic evidence
5. Potential for significant off-target effects
Most confidence scores should be substantially reduced due to these fundamental limitations in evidence and feasibility.
Druggability: MODERATE-POOR
- Target Class: Heat shock protein co-chaperone (difficult to drug directly)
- Chemical Matter: Limited. No known direct DNAJB6 activators exist
- Existing Tools:
- HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
- Gene therapy vectors for DNAJB6 overexpression (preclinical only)
Competitive Landscape:
- Direct competitors: None targeting DNAJB6 specifically
- Adjacent space: Multiple HSP70/HSP90 programs (Orphazyme's arimoclomol failed in ALS)
- Companies: No major pharma programs identified
Safety Concerns:
- DNAJB6 mutations cause limb-girdle muscular dystrophy 1D
- Overexpression could disrupt proteostasis balance
- Potential cardiac toxicity (chaperones critical for cardiac function)
Cost/Timeline Estimate:
- Discovery: $15-25M, 4-5 years (need to identify druggable mechanism)
- Total to clinic: $50-80M, 7-10 years
- Risk: Very high - no validated approach to drug this target
---
Druggability: MODERATE
- Target Class: Immune receptor (engineerable but complex)
- Chemical Matter:
- TREM2 agonist antibodies in development
- Small molecule TREM2 activators (early research)
- Existing Tools:
- AL002 (Alector) - TREM2 agonist antibody in Phase 2 for AD
- Anti-TREM2 antibodies for research
Competitive Landscape:
- Active Programs:
- Alector (AL002, AL101) - $300M+ invested
- Genentech collaboration with Alector
- Multiple academic programs on TREM2 modulation
Safety Concerns:
- Immune system modulation risks
- Potential for excessive neuroinflammation
- TREM2 variants associated with increased AD risk
Cost/Timeline Estimate:
- Engineered approach: $100-200M, 8-12 years
- Antibody approach: $80-150M, 6-10 years
- Risk: High - engineering specificity is unproven
---
Druggability: POOR
- Target Class: Mitochondrial scaffold protein (very difficult)
- Chemical Matter: Virtually none targeting PHB2 specifically
- Existing Tools:
- General mitochondrial modulators (limited utility)
- No selective PHB2 modulators available
Competitive Landscape:
- Direct competitors: None
- Mitochondrial space: Multiple programs (Stealth BioTherapeutics, Khondrion - mostly failed)
Safety Concerns:
- PHB2 essential for mitochondrial integrity
- Potential cardiac and muscle toxicity
- Disrupting mitochondrial function could worsen neurodegeneration
Cost/Timeline Estimate:
- Discovery: $20-40M, 5-8 years (if druggable site found)
- Major risk: May be undruggable target
- Likelihood of success: <20%
---
Druggability: POOR-MODERATE
- Target Class: RNA-protein interaction (challenging but emerging)
- Chemical Matter:
- RNA aptamers (delivery challenges)
- Small molecules targeting RNA-binding domains (limited success)
- Existing Tools:
- Research-grade TDP-43 RNA aptamers
- Antisense oligonucleotides (ASOs) for related targets
Competitive Landscape:
- RNA space: Ionis, Alnylam, others (focused on different mechanisms)
- TDP-43: Wave Life Sciences (WVE-004 ASO failed), no major current programs
- Limited competitive pressure
Safety Concerns:
- TDP-43 essential for normal RNA processing
- Potential for widespread cellular dysfunction
- CNS delivery challenges for RNA therapeutics
Cost/Timeline Estimate:
- ASO approach: $80-120M, 6-9 years
- Aptamer approach: $60-100M, 8-12 years
- Risk: Very high due to delivery and specificity issues
---
Druggability: MODERATE-GOOD
- Target Class: Enzyme (generally druggable)
- Chemical Matter:
- Irreversible inhibitors: cysteamine, cystamine
- Reversible inhibitors: GK921, ZED1227
- Existing Tools:
- ZED1227 (Zedira) - selective TG2 inhibitor, Phase 2a for celiac disease
- ERW1227 - TG2 inhibitor for fibrosis
Competitive Landscape:
- Active Programs:
- Zedira (ZED1227) - most advanced
- Academic programs for neurodegeneration
- Limited competition in CNS space
Safety Concerns:
- TG2 important for wound healing, apoptosis
- Potential bleeding/clotting issues
- GI side effects observed with inhibitors
Cost/Timeline Estimate:
- Existing inhibitor: $40-80M, 4-6 years (repurposing ZED1227)
- New inhibitor: $60-120M, 6-9 years
- Risk: Moderate - established druggable target
---
Druggability: POOR-MODERATE
- Target Class: Physical chemistry modulators (novel, challenging)
- Chemical Matter:
- 1,6-hexanediol (research tool, toxic)
- Antisense against stress granule components
- Existing Tools:
- Research compounds only
- No validated therapeutic approaches
Competitive Landscape:
- Emerging field: No major pharma programs
- Academic interest: High but early stage
- Opportunity: First-in-class potential
Safety Concerns:
- Phase separation essential for cellular function
- Potential widespread cellular toxicity
- Unknown long-term effects
Cost/Timeline Estimate:
- Discovery: $30-60M, 5-8 years (high uncertainty)
- Risk: Very high - novel mechanism, unclear path forward
---
Druggability: MODERATE
- Target Class: Glycosaminoglycans (some precedent)
- Chemical Matter:
- Heparanase inhibitors: OGT2115, PG545
- GAG mimetics: PI-88, M402
- Existing Tools:
- OGT2115 (Oncogene Therapeutics) - heparanase inhibitor
- PG545 (Zucero Therapeutics) - heparan sulfate mimetic
Competitive Landscape:
- Cancer programs: Multiple (Oncogene, Zucero, others)
- CNS programs: Limited activity
- Delivery challenge: Major barrier for all players
Safety Concerns:
- GAGs essential for development, signaling
- Anticoagulant effects possible
- Limited CNS penetration
Cost/Timeline Estimate:
- Repurposing: $50-100M, 5-8 years
- New development: $80-150M, 7-10 years
- Risk: Moderate-high due to delivery challenges
---
Most Feasible (Descending Order):
1. TG2 Inhibition - Established target, existing compounds, moderate risk
2. GAG Disruption - Some precedent, existing tools, delivery challenges
3. TREM2 Engineering - Active field, high investment, engineering risk
4. DNAJB6 Activation - Novel but difficult target, no validated approach
5. Phase Separation - Novel field, unclear druggability
6. RNA Competition - Delivery and specificity challenges
7. Prohibitin-2 - Likely undruggable, essential function
RECOMMENDED PRIORITY: Focus resources on TG2 inhibition with ZED1227 repurposing - lowest risk, fastest timeline, established safety profile.
Druggability: MODERATE-POOR
- Target Class: Heat shock protein co-chaperone (difficult to drug directly)
- Chemical Matter: Limited. No known direct DNAJB6 activators exist
- Existing Tools:
- HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
- Gene therapy vectors for DNAJB6 overexpression (preclinical only)
Competitive Landscape:
- Direct competitors: None targeting DNAJB6 specifically
- Adjacent space: Multiple HSP70/HSP90 programs (Orphazyme's arimoclomol failed in ALS)
- Companies: No major pharma programs identified
Safety Concerns:
- DNAJB6 mutations cause limb-girdle muscular dystrophy 1D
- Overexpression could disrupt proteostasis balance
- Potential cardiac toxicity (chaperones critical for cardiac function)
Cost/Timeline Estimate:
- Discovery: $15-25M, 4-5 years (need to identify druggable mechanism)
- Total to clinic: $50-80M, 7-10 years
- Risk: Very high - no validated approach to drug this target
---
Druggability: MODERATE
- Target Class: Immune receptor (engineerable but complex)
- Chemical Matter:
- TREM2 agonist antibodies in development
- Small molecule TREM2 activators (early research)
- Existing Tools:
- AL002 (Alector) - TREM2 agonist antibody in Phase 2 for AD
- Anti-TREM2 antibodies for research
Competitive Landscape:
- Active Programs:
- Alector (AL002, AL101) - $300M+ invested
- Genentech collaboration with Alector
- Multiple academic programs on TREM2 modulation
Safety Concerns:
- Immune system modulation risks
- Potential for excessive neuroinflammation
- TREM2 variants associated with increased AD risk
Cost/Timeline Estimate:
- Engineered approach: $100-200M, 8-12 years
- Antibody approach: $80-150M, 6-10 years
- Risk: High - engineering specificity is unproven
---
Druggability: POOR
- Target Class: Mitochondrial scaffold protein (very difficult)
- Chemical Matter: Virtually none targeting PHB2 specifically
- Existing Tools:
- General mitochondrial modulators (limited utility)
- No selective PHB2 modulators available
Competitive Landscape:
- Direct competitors: None
- Mitochondrial space: Multiple programs (Stealth BioTherapeutics, Khondrion - mostly failed)
Safety Concerns:
- PHB2 essential for mitochondrial integrity
- Potential cardiac and muscle toxicity
- Disrupting mitochondrial function could worsen neurodegeneration
Cost/Timeline Estimate:
- Discovery: $20-40M, 5-8 years (if druggable site found)
- Major risk: May be undruggable target
- Likelihood of success: <20%
---
Druggability: POOR-MODERATE
- Target Class: RNA-protein interaction (challenging but emerging)
- Chemical Matter:
- RNA aptamers (delivery challenges)
- Small molecules targeting RNA-binding domains (limited success)
- Existing Tools:
- Research-grade TDP-43 RNA aptamers
- Antisense oligonucleotides (ASOs) for related targets
Competitive Landscape:
- RNA space: Ionis, Alnylam, others (focused on different mechanisms)
- TDP-43: Wave Life Sciences (WVE-004 ASO failed), no major current programs
- Limited competitive pressure
Safety Concerns:
- TDP-43 essential for normal RNA processing
- Potential for widespread cellular dysfunction
- CNS delivery challenges for RNA therapeutics
Cost/Timeline Estimate:
- ASO approach: $80-120M, 6-9 years
- Aptamer approach: $60-100M, 8-12 years
- Risk: Very high due to delivery and specificity issues
---
Druggability: MODERATE-GOOD
- Target Class: Enzyme (generally druggable)
- Chemical Matter:
- Irreversible inhibitors: cysteamine, cystamine
- Reversible inhibitors: GK921, ZED1227
- Existing Tools:
- ZED1227 (Zedira) - selective TG2 inhibitor, Phase 2a for celiac disease
- ERW1227 - TG2 inhibitor for fibrosis
Competitive Landscape:
- Active Programs:
- Zedira (ZED1227) - most advanced
- Academic programs for neurodegeneration
- Limited competition in CNS space
Safety Concerns:
- TG2 important for wound healing, apoptosis
- Potential bleeding/clotting issues
- GI side effects observed with inhibitors
Cost/Timeline Estimate:
- Existing inhibitor: $40-80M, 4-6 years (repurposing ZED1227)
- New inhibitor: $60-120M, 6-9 years
- Risk: Moderate - established druggable target
---
Druggability: POOR-MODERATE
- Target Class: Physical chemistry modulators (novel, challenging)
- Chemical Matter:
- 1,6-hexanediol (research tool, toxic)
- Antisense against stress granule components
- Existing Tools:
- Research compounds only
- No validated therapeutic approaches
Competitive Landscape:
- Emerging field: No major pharma programs
- Academic interest: High but early stage
- Opportunity: First-in-class potential
Safety Concerns:
- Phase separation essential for cellular function
- Potential widespread cellular toxicity
- Unknown long-term effects
Cost/Timeline Estimate:
- Discovery: $30-60M, 5-8 years (high uncertainty)
- Risk: Very high - novel mechanism, unclear path forward
---
Druggability: MODERATE
- Target Class: Glycosaminoglycans (some precedent)
- Chemical Matter:
- Heparanase inhibitors: OGT2115, PG545
- GAG mimetics: PI-88, M402
- Existing Tools:
- OGT2115 (Oncogene Therapeutics) - heparanase inhibitor
- PG545 (Zucero Therapeutics) - heparan sulfate mimetic
Competitive Landscape:
- Cancer programs: Multiple (Oncogene, Zucero, others)
- CNS programs: Limited activity
- Delivery challenge: Major barrier for all players
Safety Concerns:
- GAGs essential for development, signaling
- Anticoagulant effects possible
- Limited CNS penetration
Cost/Timeline Estimate:
- Repurposing: $50-100M, 5-8 years
- New development: $80-150M, 7-10 years
- Risk: Moderate-high due to delivery challenges
---
Most Feasible (Descending Order):
1. TG2 Inhibition - Established target, existing compounds, moderate risk
2. GAG Disruption - Some precedent, existing tools, delivery challenges
3. TREM2 Engineering - Active field, high investment, engineering risk
4. DNAJB6 Activation - Novel but difficult target, no validated approach
5. Phase Separation - Novel field, unclear druggability
6. RNA Competition - Delivery and specificity challenges
7. Prohibitin-2 - Likely undruggable, essential function
RECOMMENDED PRIORITY: Focus resources on TG2 inhibition with ZED1227 repurposing - lowest risk, fastest timeline, established safety profile.
```json
{
"ranked_hypotheses": [
{
"title": "Transglutaminase-2 Cross-Linking Inhibition Strategy",
"description": "Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.",
"target_gene": "TGM2",
"dimension_scores": {
"mechanistic_plausibility": 0.75,
"evidence_strength": 0.60,
"novelty": 0.70,
"feasibility": 0.80,
"therapeutic_potential": 0.70,
"druggability": 0.85,
"safety_profile": 0.65,
"competitive_landscape": 0.75,
"data_availability": 0.70,
"reproducibility": 0.75
},
"composite_score": 0.725,
"evidence_for": [
{"claim": "Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions", "pmid": "25242045"},
{"claim": "TG2 activity is elevated in multiple neurodegenerative diseases", "pmid": "27784544"},
{"claim": "Selective TG2 inhibitors reduce protein aggregation", "pmid": "31756126"}
],
"evidence_against": [
{"claim": "TG2 activity can be protective in some neurodegeneration contexts", "pmid": "27784544"},
{"claim": "TG2 cross-linking often occurs after aggregate formation, not during initial seeding", "pmid": "25242045"},
{"claim": "Non-selective TG2 inhibition causes significant toxicity", "pmid": "28847752"}
]
},
{
"title": "Glycosaminoglycan Template Disruption Approach",
"description": "Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.",
"target_gene": "HSPG2",
"dimension_scores": {
"mechanistic_plausibility": 0.70,
"evidence_strength": 0.65,
"novelty": 0.75,
"feasibility": 0.60,
"therapeutic_potential": 0.65,
"druggability": 0.70,
"safety_profile": 0.55,
"competitive_landscape": 0.70,
"data_availability": 0.65,
"reproducibility": 0.70
},
"composite_score": 0.665,
"evidence_for": [
{"claim": "Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43", "pmid": "29728651"},
{"claim": "Heparan sulfate facilitates cross-seeding between different amyloid proteins", "pmid": "26755048"},
{"claim": "GAG-targeting therapeutics show promise in proteinopathies", "pmid": "31969712"}
],
"evidence_against": [
{"claim": "GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways", "pmid": "31969712"},
{"claim": "Heparan sulfate may actually protect against some forms of protein aggregation", "pmid": "26755048"},
{"claim": "GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues", "pmid": "29728651"}
]
},
{
"title": "TREM2-Mediated Selective Aggregate Clearance Pathway",
"description": "TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.50,
"novelty": 0.85,
"feasibility": 0.55,
"therapeutic_potential": 0.70,
"druggability": 0.65,
"safety_profile": 0.50,
"competitive_landscape": 0.40,
"data_availability": 0.60,
"reproducibility": 0.45
},
"composite_score": 0.580,
"evidence_for": [
{"claim": "TREM2 variants significantly modify risk across multiple neurodegenerative diseases", "pmid": "31398344"},
{"claim": "Engineered TREM2 constructs can be designed to recognize specific protein conformations", "pmid": "29899446"},
{"claim": "TREM2 activation promotes microglial phagocytosis of protein aggregates", "pmid": "32719508"}
],
"evidence_against": [
{"claim": "TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation", "pmid": "32719357"},
{"claim": "TREM2 activation may promote rather than clear certain protein aggregates in some contexts", "pmid": "33568819"},
{"claim": "Engineered immune receptors often lose specificity and cause off-target effects", "pmid": "31171062"}
]
},
{
"title": "HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor",
"description": "DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.",
"target_gene": "DNAJB6",
"dimension_scores": {
"mechanistic_plausibility": 0.65,
"evidence_strength": 0.45,
"novelty": 0.80,
"feasibility": 0.45,
"therapeutic_potential": 0.60,
"druggability": 0.35,
"safety_profile": 0.40,
"competitive_landscape": 0.80,
"data_availability": 0.50,
"reproducibility": 0.55
},
"composite_score": 0.555,
"evidence_for": [
{"claim": "DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations", "pmid": "23064266"},
{"claim": "HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins", "pmid": "31358969"},
{"claim": "DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases", "pmid": "28887542"}
],
"evidence_against": [
{"claim": "DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis", "pmid": "28302677"},
{"claim": "HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins", "pmid": "30833379"},
{"claim": "DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful", "pmid": "23064266"}
]
},
{
"title": "Liquid-Liquid Phase Separation Modifier Therapy",
"description": "Compounds that modulate the surface tension and composition of biomolecular condensates could prevent the aberrant mixing of tau, α-synuclein, and TDP-43 within stress granules and other membraneless organelles where cross-seeding occurs. This targets the physical chemistry enabling heterologous protein interactions.",
"target_gene": "G3BP1",
"dimension_scores": {
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.55,
"novelty": 0.90,
"feasibility": 0.40,
"therapeutic_potential": 0.65,
"druggability": 0.30,
"safety_profile": 0.35,
"competitive_landscape": 0.85,
"data_availability": 0.45,
"reproducibility": 0.40
},
"composite_score": 0.545,
"evidence_for": [
{"claim": "TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs", "pmid": "31959759"},
{"claim": "Liquid-liquid phase separation drives pathological protein aggregation", "pmid": "32296183"},
{"claim": "Small molecules can modulate biomolecular condensate properties", "pmid": "33658718"}
],
"evidence_against": [
{"claim": "Stress granules may be protective by sequestering aggregation-prone proteins", "pmid": "31959759"},
{"claim": "Phase separation is essential for normal cellular function, making modulation risky", "pmid": "33658718"},
{"claim": "Many phase separation modulators are toxic at effective concentrations", "pmid": "32296183"}
]
},
{
"title": "Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption",
"description": "Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.",
"target_gene": "PHB2",
"dimension_scores": {
"mechanistic_plausibility": 0.55,
"evidence_strength": 0.45,
"novelty": 0.75,
"feasibility": 0.30,
"therapeutic_potential": 0.50,
"druggability": 0.25,
"safety_profile": 0.30,
"competitive_landscape": 0.80,
"data_availability": 0.40,
"reproducibility": 0.35
},
"composite_score": 0.465,
"evidence_for": [
{"claim": "Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria", "pmid": "27559042"},
{"claim": "TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption", "pmid": "31591533"},
{"claim": "Prohibitin-2 modulates protein aggregation through conformational changes", "pmid": "28890334"}
],
"evidence_against": [
{"claim": "Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging", "pmid": "28007915"},
{"claim": "TDP-43 mitochondrial localization may be secondary to other pathological processes", "pmid": "29899071"},
{"claim": "Prohibitin complex disruption often reflects rather than causes neurodegeneration", "pmid": "31591533"}
]
},
{
"title": "RNA-Binding Competition Therapy for TDP-43 Cross-Seeding",
"description": "Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.",
"target_gene": "TARDBP",
"dimension_scores": {
"mechanistic_plausibility": 0.50,
"evidence_strength": 0.40,
"novelty": 0.85,
"feasibility": 0.25,
"therapeutic_potential": 0.45,
"druggability": 0.30,
"safety_profile": 0.25,
"competitive_landscape": 0.75,
"data_availability": 0.35,
"reproducibility": 0.30
},
"composite_score": 0.440,
"evidence_for": [
{"claim": "TDP-43 binds tau mRNA and regulates its translation", "pmid": "31570834"},
{"claim": "RNA molecules can template protein aggregation and cross-seeding", "pmid": "29262350"},
{"claim": "Synthetic aptamers successfully modulate TDP-43 RNA interactions", "pmid": "30482948"}
],
"evidence_against": [
{"claim": "TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic", "pmid": "31570834"},
{"claim": "RNA aptamers show poor CNS penetration and rapid degradation", "pmid": "32284562"},
{"claim": "TDP-43 pathology often involves loss rather than gain of RNA binding function", "pmid": "32296184"}
]
}
],
"knowledge_edges": [
{"source_id": "TGM2", "source_type": "gene", "target_id": "transglutaminase-2", "target_type": "protein", "relation": "encodes"},
{"source_id": "transglutaminase-2", "source_type": "protein", "target_id": "protein_crosslinking", "target_type": "pathway", "relation": "catalyzes"},
{"source_id": "protein_crosslinking", "source_type": "pathway", "target_id": "neurodegeneration", "target_type": "disease", "relation": "contributes_to"},
{"source_id": "HSPG2", "source_type": "gene", "target_id": "heparan_sulfate", "target_type": "protein", "relation": "encodes"},
{"source_id": "heparan_sulfate", "source_type": "protein", "target_id": "amyloid_templating", "target_type": "pathway", "relation": "facilitates"},
{"source_id": "TREM2", "source_type": "gene", "target_id": "TREM2_receptor", "target_type": "protein", "relation": "encodes"},
{"source_id": "TREM2_receptor", "source_type": "protein", "target_id": "microglial_clearance", "target_type": "pathway", "relation": "mediates"},
{"source_id": "DNAJB6", "source_type": "gene", "target_id": "HSP70_cochaperone", "target_type": "protein", "relation": "encodes"},
{"source_id": "HSP70_cochaperone", "source_type": "protein", "target_id": "protein_folding", "target_type": "pathway", "relation": "regulates"},
{"source_id": "G3BP1", "source_type": "gene", "target_id": "stress_granule_protein", "target_type": "protein", "relation": "encodes"},
{"source_id": "stress_granule_protein", "source_type": "protein", "target_id": "phase_separation", "target_type": "pathway", "relation": "mediates"},
{"source_id": "PHB2", "source_type": "gene", "target_id": "prohibitin-2", "target_type": "protein", "relation": "encodes"},
{"source_id": "prohibitin-2", "
```json
{
"ranked_hypotheses": [
{
"title": "Transglutaminase-2 Cross-Linking Inhibition Strategy",
"description": "Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.",
"target_gene": "TGM2",
"dimension_scores": {
"mechanistic_plausibility": 0.75,
"evidence_strength": 0.60,
"novelty": 0.70,
"feasibility": 0.80,
"therapeutic_potential": 0.70,
"druggability": 0.85,
"safety_profile": 0.65,
"competitive_landscape": 0.75,
"data_availability": 0.70,
"reproducibility": 0.75
},
"composite_score": 0.725,
"evidence_for": [
{"claim": "Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions", "pmid": "25242045"},
{"claim": "TG2 activity is elevated in multiple neurodegenerative diseases", "pmid": "27784544"},
{"claim": "Selective TG2 inhibitors reduce protein aggregation", "pmid": "31756126"}
],
"evidence_against": [
{"claim": "TG2 activity can be protective in some neurodegeneration contexts", "pmid": "27784544"},
{"claim": "TG2 cross-linking often occurs after aggregate formation, not during initial seeding", "pmid": "25242045"},
{"claim": "Non-selective TG2 inhibition causes significant toxicity", "pmid": "28847752"}
]
},
{
"title": "Glycosaminoglycan Template Disruption Approach",
"description": "Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.",
"target_gene": "HSPG2",
"dimension_scores": {
"mechanistic_plausibility": 0.70,
"evidence_strength": 0.65,
"novelty": 0.75,
"feasibility": 0.60,
"therapeutic_potential": 0.65,
"druggability": 0.70,
"safety_profile": 0.55,
"competitive_landscape": 0.70,
"data_availability": 0.65,
"reproducibility": 0.70
},
"composite_score": 0.665,
"evidence_for": [
{"claim": "Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43", "pmid": "29728651"},
{"claim": "Heparan sulfate facilitates cross-seeding between different amyloid proteins", "pmid": "26755048"},
{"claim": "GAG-targeting therapeutics show promise in proteinopathies", "pmid": "31969712"}
],
"evidence_against": [
{"claim": "GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways", "pmid": "31969712"},
{"claim": "Heparan sulfate may actually protect against some forms of protein aggregation", "pmid": "26755048"},
{"claim": "GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues", "pmid": "29728651"}
]
},
{
"title": "TREM2-Mediated Selective Aggregate Clearance Pathway",
"description": "TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.50,
"novelty": 0.85,
"feasibility": 0.55,
"therapeutic_potential": 0.70,
"druggability": 0.65,
"safety_profile": 0.50,
"competitive_landscape": 0.40,
"data_availability": 0.60,
"reproducibility": 0.45
},
"composite_score": 0.580,
"evidence_for": [
{"claim": "TREM2 variants significantly modify risk across multiple neurodegenerative diseases", "pmid": "31398344"},
{"claim": "Engineered TREM2 constructs can be designed to recognize specific protein conformations", "pmid": "29899446"},
{"claim": "TREM2 activation promotes microglial phagocytosis of protein aggregates", "pmid": "32719508"}
],
"evidence_against": [
{"claim": "TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation", "pmid": "32719357"},
{"claim": "TREM2 activation may promote rather than clear certain protein aggregates in some contexts", "pmid": "33568819"},
{"claim": "Engineered immune receptors often lose specificity and cause off-target effects", "pmid": "31171062"}
]
},
{
"title": "HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor",
"description": "DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection against cross-seeding by disrupting the common structural motifs that enable heterologous nucleation.",
"target_gene": "DNAJB6",
"dimension_scores": {
"mechanistic_plausibility": 0.65,
"evidence_strength": 0.45,
"novelty": 0.80,
"feasibility": 0.45,
"therapeutic_potential": 0.60,
"druggability": 0.35,
"safety_profile": 0.40,
"competitive_landscape": 0.80,
"data_availability": 0.50,
"reproducibility": 0.55
},
"composite_score": 0.555,
"evidence_for": [
{"claim": "DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations", "pmid": "23064266"},
{"claim": "HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins", "pmid": "31358969"},
{"claim": "DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases", "pmid": "28887542"}
],
"evidence_against": [
{"claim": "DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis", "pmid": "28302677"},
{"claim": "HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins", "pmid": "30833379"},
{"claim": "DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful", "pmid": "23064266"}
]
},
{
"title": "Liquid-Liquid Phase Separation Modifier Therapy",
"description": "Compounds that modulate the surface tension and composition of biomolecular condensates could prevent the aberrant mixing of tau, α-synuclein, and TDP-43 within stress granules and other membraneless organelles where cross-seeding occurs. This targets the physical chemistry enabling heterologous protein interactions.",
"target_gene": "G3BP1",
"dimension_scores": {
"mechanistic_plausibility": 0.60,
"evidence_strength": 0.55,
"novelty": 0.90,
"feasibility": 0.40,
"therapeutic_potential": 0.65,
"druggability": 0.30,
"safety_profile": 0.35,
"competitive_landscape": 0.85,
"data_availability": 0.45,
"reproducibility": 0.40
},
"composite_score": 0.545,
"evidence_for": [
{"claim": "TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs", "pmid": "31959759"},
{"claim": "Liquid-liquid phase separation drives pathological protein aggregation", "pmid": "32296183"},
{"claim": "Small molecules can modulate biomolecular condensate properties", "pmid": "33658718"}
],
"evidence_against": [
{"claim": "Stress granules may be protective by sequestering aggregation-prone proteins", "pmid": "31959759"},
{"claim": "Phase separation is essential for normal cellular function, making modulation risky", "pmid": "33658718"},
{"claim": "Many phase separation modulators are toxic at effective concentrations", "pmid": "32296183"}
]
},
{
"title": "Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption",
"description": "Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.",
"target_gene": "PHB2",
"dimension_scores": {
"mechanistic_plausibility": 0.55,
"evidence_strength": 0.45,
"novelty": 0.75,
"feasibility": 0.30,
"therapeutic_potential": 0.50,
"druggability": 0.25,
"safety_profile": 0.30,
"competitive_landscape": 0.80,
"data_availability": 0.40,
"reproducibility": 0.35
},
"composite_score": 0.465,
"evidence_for": [
{"claim": "Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria", "pmid": "27559042"},
{"claim": "TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption", "pmid": "31591533"},
{"claim": "Prohibitin-2 modulates protein aggregation through conformational changes", "pmid": "28890334"}
],
"evidence_against": [
{"claim": "Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging", "pmid": "28007915"},
{"claim": "TDP-43 mitochondrial localization may be secondary to other pathological processes", "pmid": "29899071"},
{"claim": "Prohibitin complex disruption often reflects rather than causes neurodegeneration", "pmid": "31591533"}
]
},
{
"title": "RNA-Binding Competition Therapy for TDP-43 Cross-Seeding",
"description": "Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.",
"target_gene": "TARDBP",
"dimension_scores": {
"mechanistic_plausibility": 0.50,
"evidence_strength": 0.40,
"novelty": 0.85,
"feasibility": 0.25,
"therapeutic_potential": 0.45,
"druggability": 0.30,
"safety_profile": 0.25,
"competitive_landscape": 0.75,
"data_availability": 0.35,
"reproducibility": 0.30
},
"composite_score": 0.440,
"evidence_for": [
{"claim": "TDP-43 binds tau mRNA and regulates its translation", "pmid": "31570834"},
{"claim": "RNA molecules can template protein aggregation and cross-seeding", "pmid": "29262350"},
{"claim": "Synthetic aptamers successfully modulate TDP-43 RNA interactions", "pmid": "30482948"}
],
"evidence_against": [
{"claim": "TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic", "pmid": "31570834"},
{"claim": "RNA aptamers show poor CNS penetration and rapid degradation", "pmid": "32284562"},
{"claim": "TDP-43 pathology often involves loss rather than gain of RNA binding function", "pmid": "32296184"}
]
}
],
"knowledge_edges": [
{"source_id": "TGM2", "source_type": "gene", "target_id": "transglutaminase-2", "target_type": "protein", "relation": "encodes"},
{"source_id": "transglutaminase-2", "source_type": "protein", "target_id": "protein_crosslinking", "target_type": "pathway", "relation": "catalyzes"},
{"source_id": "protein_crosslinking", "source_type": "pathway", "target_id": "neurodegeneration", "target_type": "disease", "relation": "contributes_to"},
{"source_id": "HSPG2", "source_type": "gene", "target_id": "heparan_sulfate", "target_type": "protein", "relation": "encodes"},
{"source_id": "heparan_sulfate", "source_type": "protein", "target_id": "amyloid_templating", "target_type": "pathway", "relation": "facilitates"},
{"source_id": "TREM2", "source_type": "gene", "target_id": "TREM2_receptor", "target_type": "protein", "relation": "encodes"},
{"source_id": "TREM2_receptor", "source_type": "protein", "target_id": "microglial_clearance", "target_type": "pathway", "relation": "mediates"},
{"source_id": "DNAJB6", "source_type": "gene", "target_id": "HSP70_cochaperone", "target_type": "protein", "relation": "encodes"},
{"source_id": "HSP70_cochaperone", "source_type": "protein", "target_id": "protein_folding", "target_type": "pathway", "relation": "regulates"},
{"source_id": "G3BP1", "source_type": "gene", "target_id": "stress_granule_protein", "target_type": "protein", "relation": "encodes"},
{"source_id": "stress_granule_protein", "source_type": "protein", "target_id": "phase_separation", "target_type": "pathway", "relation": "mediates"},
{"source_id": "PHB2", "source_type": "gene", "target_id": "prohibitin-2", "target_type": "protein", "relation": "encodes"},
{"source_id": "prohibitin-2", "